$ALXN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ALEXION PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ALEXION PHARMACEUTICALS, INC.. Get notifications about new insider transactions in ALEXION PHARMACEUTICALS, INC. for free.
Page: < prev 1 2 3 4 5 6 7 ... 22 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Grant | A | 0.00 | 12,800 | 0 | 51,058 | 38.3 K to 51.1 K (+33.46 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Sell | S | 131.70 | 625 | 82,313 | 38,258 | 38.9 K to 38.3 K (-1.61 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Sell | S | 131.20 | 860 | 112,832 | 38,883 | 39.7 K to 38.9 K (-2.16 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Option Exercise | A | 131.25 | 14,800 | 1,942,500 | 29,600 | |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Grant | A | 0.00 | 7,500 | 0 | 37,643 | 30.1 K to 37.6 K (+24.88 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 0.00 | 54 | 0 | 30,143 | 30.2 K to 30.1 K (-0.18 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 131.20 | 71 | 9,315 | 30,197 | 30.3 K to 30.2 K (-0.23 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Option Exercise | A | 131.25 | 12,800 | 1,680,000 | 25,600 | |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Sell | S | 132.50 | 404 | 53,530 | 39,161 | 39.6 K to 39.2 K (-1.02 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Grant | A | 0.00 | 6,500 | 0 | 39,565 | 33.1 K to 39.6 K (+19.66 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Sell | S | 131.71 | 915 | 120,515 | 33,065 | 34 K to 33.1 K (-2.69 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Sell | S | 131.20 | 860 | 112,832 | 33,980 | 34.8 K to 34 K (-2.47 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Option Exercise | A | 131.25 | 8,700 | 1,141,875 | 8,700 | |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Grant | A | 0.00 | 4,400 | 0 | 33,410 | 29 K to 33.4 K (+15.17 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 132.50 | 156 | 20,670 | 29,010 | 29.2 K to 29 K (-0.53 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 131.70 | 480 | 63,216 | 29,166 | 29.6 K to 29.2 K (-1.62 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 131.20 | 358 | 46,970 | 29,646 | 30 K to 29.6 K (-1.19 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 132.50 | 1,240 | 164,300 | 390,670 | 391.9 K to 390.7 K (-0.32 %) |
Mar 01 2017 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 131.71 | 2,738 | 360,622 | 391,910 | 394.6 K to 391.9 K (-0.69 %) |
Feb 10 2017 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 126.84 | 246 | 31,203 | 394,648 | 394.9 K to 394.6 K (-0.06 %) |
Feb 10 2017 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Sell | S | 126.84 | 167 | 21,182 | 34,840 | 35 K to 34.8 K (-0.48 %) |
Feb 10 2017 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Sell | S | 126.84 | 217 | 27,524 | 39,743 | 40 K to 39.7 K (-0.54 %) |
Feb 10 2017 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 126.84 | 167 | 21,182 | 46,476 | 46.6 K to 46.5 K (-0.36 %) |
Feb 08 2017 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Sell | S | 128.09 | 166 | 21,263 | 35,007 | 35.2 K to 35 K (-0.47 %) |
Feb 08 2017 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Sell | S | 126.65 | 24 | 3,040 | 35,173 | 35.2 K to 35.2 K (-0.07 %) |
Feb 08 2017 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Sell | S | 125.69 | 3,380 | 424,832 | 35,197 | 38.6 K to 35.2 K (-8.76 %) |
Feb 08 2017 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 125.69 | 2,795 | 351,304 | 32,589 | 35.4 K to 32.6 K (-7.90 %) |
Feb 08 2017 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 128.09 | 135 | 17,292 | 46,643 | 46.8 K to 46.6 K (-0.29 %) |
Feb 08 2017 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 126.38 | 23 | 2,907 | 46,778 | 46.8 K to 46.8 K (-0.05 %) |
Feb 08 2017 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 125.69 | 3,380 | 424,832 | 46,801 | 50.2 K to 46.8 K (-6.74 %) |
Feb 08 2017 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 128.09 | 1,010 | 129,371 | 394,894 | 395.9 K to 394.9 K (-0.26 %) |
Feb 08 2017 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 126.09 | 75 | 9,457 | 395,904 | 396 K to 395.9 K (-0.02 %) |
Feb 08 2017 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 125.69 | 7,640 | 960,272 | 395,979 | 403.6 K to 396 K (-1.89 %) |
Feb 08 2017 | ALXN | ALEXION PHARMACEUT ... | Miller Edward | SVP, Chief Complian ... | Sell | S | 126.95 | 9 | 1,143 | 15,474 | 15.5 K to 15.5 K (-0.06 %) |
Feb 08 2017 | ALXN | ALEXION PHARMACEUT ... | Miller Edward | SVP, Chief Complian ... | Sell | S | 125.69 | 1,036 | 130,215 | 15,483 | 16.5 K to 15.5 K (-6.27 %) |
Feb 08 2017 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 125.69 | 165 | 20,739 | 30,268 | 30.4 K to 30.3 K (-0.54 %) |
Feb 08 2017 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Sell | S | 126.88 | 18 | 2,284 | 39,960 | 40 K to 40 K (-0.05 %) |
Feb 08 2017 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Sell | S | 125.69 | 2,710 | 340,620 | 39,978 | 42.7 K to 40 K (-6.35 %) |
Feb 08 2017 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 128.09 | 222 | 28,436 | 30,004 | 30.2 K to 30 K (-0.73 %) |
Feb 08 2017 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 126.04 | 15 | 1,891 | 30,226 | 30.2 K to 30.2 K (-0.05 %) |
Feb 08 2017 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 125.69 | 1,695 | 213,045 | 30,241 | 31.9 K to 30.2 K (-5.31 %) |
Jan 13 2017 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Option Exercise | S | 22.90 | 100 | 2,290 | 76,838 | |
Jan 13 2017 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 144.99 | 100 | 14,499 | 403,619 | 403.7 K to 403.6 K (-0.02 %) |
Jan 13 2017 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Buy | M | 22.90 | 100 | 2,290 | 403,719 | 403.6 K to 403.7 K (+0.02 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Option Exercise | M | 96.35 | 3,425 | 329,999 | 0 | |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Option Exercise | M | 85.75 | 3,237 | 277,573 | 0 | |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Option Exercise | M | 49.43 | 5,572 | 275,424 | 0 | |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Option Exercise | M | 26.64 | 7,932 | 211,308 | 0 | |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 141.22 | 22 | 3,107 | 3,880 | 3.9 K to 3.9 K (-0.56 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 140.59 | 117 | 16,449 | 3,902 | 4 K to 3.9 K (-2.91 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 139.49 | 435 | 60,678 | 4,019 | 4.5 K to 4 K (-9.77 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 138.60 | 421 | 58,351 | 4,454 | 4.9 K to 4.5 K (-8.64 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 137.56 | 599 | 82,398 | 4,875 | 5.5 K to 4.9 K (-10.94 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 135.69 | 31 | 4,206 | 5,474 | 5.5 K to 5.5 K (-0.56 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 133.95 | 15 | 2,009 | 5,505 | 5.5 K to 5.5 K (-0.27 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 133.65 | 853 | 114,003 | 5,520 | 6.4 K to 5.5 K (-13.38 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 141.23 | 278 | 39,262 | 6,373 | 6.7 K to 6.4 K (-4.18 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 140.59 | 1,433 | 201,465 | 6,651 | 8.1 K to 6.7 K (-17.73 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 139.49 | 5,350 | 746,272 | 8,084 | 13.4 K to 8.1 K (-39.82 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 138.60 | 5,176 | 717,394 | 13,434 | 18.6 K to 13.4 K (-27.81 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 137.56 | 7,375 | 1,014,505 | 18,610 | 26 K to 18.6 K (-28.38 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 135.70 | 369 | 50,073 | 25,985 | 26.4 K to 26 K (-1.40 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 133.95 | 185 | 24,781 | 26,354 | 26.5 K to 26.4 K (-0.70 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Buy | M | 96.35 | 3,425 | 329,999 | 26,539 | 23.1 K to 26.5 K (+14.82 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Buy | M | 85.75 | 3,237 | 277,573 | 23,114 | 19.9 K to 23.1 K (+16.29 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Buy | M | 49.43 | 5,572 | 275,424 | 19,877 | 14.3 K to 19.9 K (+38.95 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Buy | M | 26.64 | 7,932 | 211,308 | 14,305 | 6.4 K to 14.3 K (+124.46 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Option Exercise | M | 22.90 | 4,853 | 111,134 | 76,938 | |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Option Exercise | M | 22.90 | 34,210 | 783,409 | 81,791 | |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 144.90 | 334 | 48,397 | 403,285 | 403.6 K to 403.3 K (-0.08 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 144.93 | 4,853 | 703,345 | 403,619 | 408.5 K to 403.6 K (-1.19 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Buy | M | 22.90 | 4,853 | 111,134 | 408,472 | 403.6 K to 408.5 K (+1.20 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 139.90 | 334 | 46,727 | 403,619 | 404 K to 403.6 K (-0.08 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 134.90 | 334 | 45,057 | 403,953 | 404.3 K to 404 K (-0.08 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 139.98 | 17,105 | 2,394,358 | 404,287 | 421.4 K to 404.3 K (-4.06 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 135.07 | 17,105 | 2,310,372 | 421,392 | 438.5 K to 421.4 K (-3.90 %) |
Jan 09 2017 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Buy | M | 22.90 | 34,210 | 783,409 | 438,497 | 404.3 K to 438.5 K (+8.46 %) |
Dec 13 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 130.00 | 2,308 | 300,040 | 30,433 | 32.7 K to 30.4 K (-7.05 %) |
Dec 13 2016 | ALXN | ALEXION PHARMACEUT ... | ANDERSON DAVID J | EVP, Chief Financia ... | Grant | A | 0.00 | 8,689 | 0 | 8,689 | 0 to 8.7 K |
Dec 13 2016 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 118.61 | 1,044 | 123,829 | 50,181 | 51.2 K to 50.2 K (-2.04 %) |
Nov 16 2016 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 115.10 | 59 | 6,791 | 31,936 | 32 K to 31.9 K (-0.18 %) |
Nov 07 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Option Exercise | M | 22.90 | 36,649 | 839,262 | 116,001 | |
Nov 07 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 145.06 | 3,739 | 542,379 | 404,287 | 408 K to 404.3 K (-0.92 %) |
Nov 07 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 141.84 | 831 | 117,869 | 408,026 | 408.9 K to 408 K (-0.20 %) |
Nov 07 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 140.83 | 8,521 | 1,200,012 | 408,857 | 417.4 K to 408.9 K (-2.04 %) |
Nov 07 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 139.98 | 11,838 | 1,657,083 | 417,378 | 429.2 K to 417.4 K (-2.76 %) |
Nov 07 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 139.05 | 9,020 | 1,254,231 | 429,216 | 438.2 K to 429.2 K (-2.06 %) |
Nov 07 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 137.77 | 2,600 | 358,202 | 438,236 | 440.8 K to 438.2 K (-0.59 %) |
Nov 07 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 136.00 | 100 | 13,600 | 440,836 | 440.9 K to 440.8 K (-0.02 %) |
Nov 07 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Buy | M | 22.90 | 36,649 | 839,262 | 440,936 | 404.3 K to 440.9 K (+9.07 %) |
Nov 07 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 144.90 | 334 | 48,397 | 404,287 | 404.6 K to 404.3 K (-0.08 %) |
Nov 07 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 139.90 | 334 | 46,727 | 404,621 | 405 K to 404.6 K (-0.08 %) |
Nov 02 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Option Exercise | M | 22.90 | 1,300 | 29,770 | 152,650 | |
Nov 02 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 135.37 | 334 | 45,214 | 404,955 | 405.3 K to 405 K (-0.08 %) |
Nov 02 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 135.28 | 1,300 | 175,864 | 405,289 | 406.6 K to 405.3 K (-0.32 %) |
Nov 02 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Buy | M | 22.90 | 1,300 | 29,770 | 406,589 | 405.3 K to 406.6 K (+0.32 %) |
Oct 18 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 120.28 | 4,584 | 551,364 | 32,741 | 37.3 K to 32.7 K (-12.28 %) |
Oct 05 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 122.41 | 29 | 3,550 | 37,325 | 37.4 K to 37.3 K (-0.08 %) |
Oct 05 2016 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 122.41 | 120 | 14,689 | 31,995 | 32.1 K to 32 K (-0.37 %) |
Sep 27 2016 | ALXN | ALEXION PHARMACEUT ... | NORBY R DOUGLAS | Director | Sell | M | 131.97 | 1,774 | 234,115 | 2,876 | 4.7 K to 2.9 K (-38.15 %) |
Sep 27 2016 | ALXN | ALEXION PHARMACEUT ... | NORBY R DOUGLAS | Director | Sell | M | 131.10 | 3,724 | 488,216 | 4,650 | 8.4 K to 4.7 K (-44.47 %) |
Sep 27 2016 | ALXN | ALEXION PHARMACEUT ... | NORBY R DOUGLAS | Director | Sell | M | 130.03 | 2,800 | 364,084 | 8,374 | 11.2 K to 8.4 K (-25.06 %) |
Sep 27 2016 | ALXN | ALEXION PHARMACEUT ... | NORBY R DOUGLAS | Director | Sell | M | 128.81 | 7,202 | 927,690 | 11,174 | 18.4 K to 11.2 K (-39.19 %) |
Sep 14 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 129.00 | 3,000 | 387,000 | 37,354 | 40.4 K to 37.4 K (-7.43 %) |
Sep 14 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 124.20 | 225 | 27,945 | 40,354 | 40.6 K to 40.4 K (-0.55 %) |
Sep 09 2016 | ALXN | ALEXION PHARMACEUT ... | Miller Edward | SVP, Chief Complian ... | Sell | S | 128.32 | 367 | 47,093 | 16,519 | 16.9 K to 16.5 K (-2.17 %) |
Sep 08 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 125.94 | 1,000 | 125,940 | 40,579 | 41.6 K to 40.6 K (-2.41 %) |
Sep 02 2016 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 126.29 | 650 | 82,089 | 35,384 | 36 K to 35.4 K (-1.80 %) |
Sep 01 2016 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Sell | S | 127.76 | 1,000 | 127,760 | 38,577 | 39.6 K to 38.6 K (-2.53 %) |
Aug 24 2016 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Option Exercise | M | 18.01 | 15,000 | 270,150 | 0 | |
Aug 24 2016 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 136.53 | 15,000 | 2,047,950 | 6,373 | 21.4 K to 6.4 K (-70.18 %) |
Aug 24 2016 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Buy | M | 18.01 | 15,000 | 270,150 | 21,373 | 6.4 K to 21.4 K (+235.37 %) |
Aug 24 2016 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 135.51 | 700 | 94,857 | 6,373 | 7.1 K to 6.4 K (-9.90 %) |
Aug 10 2016 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 137.14 | 222 | 30,445 | 32,115 | 32.3 K to 32.1 K (-0.69 %) |
Aug 10 2016 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 137.14 | 277 | 37,988 | 178,463 | 178.7 K to 178.5 K (-0.15 %) |
Aug 10 2016 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 137.14 | 135 | 18,514 | 51,225 | 51.4 K to 51.2 K (-0.26 %) |
Aug 10 2016 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Sell | S | 137.14 | 165 | 22,628 | 39,577 | 39.7 K to 39.6 K (-0.42 %) |
Aug 10 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Sell | S | 137.14 | 332 | 45,530 | 189,266 | 189.6 K to 189.3 K (-0.18 %) |
Aug 10 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 137.14 | 1,010 | 138,511 | 405,289 | 406.3 K to 405.3 K (-0.25 %) |
May 19 2016 | ALXN | ALEXION PHARMACEUT ... | Brennan David R | Director | Option Exercise | A | 138.86 | 2,294 | 318,545 | 2,294 | |
May 19 2016 | ALXN | ALEXION PHARMACEUT ... | Brennan David R | Director | Grant | A | 0.00 | 835 | 0 | 2,803 | 2 K to 2.8 K (+42.43 %) |
May 18 2016 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Sell | S | 140.43 | 18 | 2,528 | 42,688 | 42.7 K to 42.7 K (-0.04 %) |
May 18 2016 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Sell | S | 139.19 | 4,079 | 567,756 | 42,706 | 46.8 K to 42.7 K (-8.72 %) |
May 13 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Option Exercise | A | 138.86 | 2,294 | 318,545 | 2,294 | |
May 13 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Grant | A | 0.00 | 835 | 0 | 406,299 | 405.5 K to 406.3 K (+0.21 %) |
May 13 2016 | ALXN | ALEXION PHARMACEUT ... | Veneman Ann M | Director | Option Exercise | A | 138.86 | 2,294 | 318,545 | 2,294 | |
May 13 2016 | ALXN | ALEXION PHARMACEUT ... | Veneman Ann M | Director | Grant | A | 0.00 | 835 | 0 | 4,985 | 4.2 K to 5 K (+20.12 %) |
May 13 2016 | ALXN | ALEXION PHARMACEUT ... | COUGHLIN CHRISTOPHER J | Director | Option Exercise | A | 138.86 | 2,294 | 318,545 | 2,294 | |
May 13 2016 | ALXN | ALEXION PHARMACEUT ... | COUGHLIN CHRISTOPHER J | Director | Grant | A | 0.00 | 835 | 0 | 2,303 | 1.5 K to 2.3 K (+56.88 %) |
May 13 2016 | ALXN | ALEXION PHARMACEUT ... | NORBY R DOUGLAS | Director | Option Exercise | A | 138.86 | 2,294 | 318,545 | 2,294 | |
May 13 2016 | ALXN | ALEXION PHARMACEUT ... | NORBY R DOUGLAS | Director | Grant | A | 0.00 | 835 | 0 | 18,376 | 17.5 K to 18.4 K (+4.76 %) |
May 13 2016 | ALXN | ALEXION PHARMACEUT ... | Rummelt Andreas | Director | Option Exercise | A | 138.86 | 2,294 | 318,545 | 2,294 | |
May 13 2016 | ALXN | ALEXION PHARMACEUT ... | Rummelt Andreas | Director | Grant | A | 0.00 | 835 | 0 | 15,216 | 14.4 K to 15.2 K (+5.81 %) |
May 13 2016 | ALXN | ALEXION PHARMACEUT ... | Mollen John T | Director | Option Exercise | A | 138.86 | 2,294 | 318,545 | 2,294 | |
May 13 2016 | ALXN | ALEXION PHARMACEUT ... | Mollen John T | Director | Grant | A | 0.00 | 835 | 0 | 2,303 | 1.5 K to 2.3 K (+56.88 %) |
May 13 2016 | ALXN | ALEXION PHARMACEUT ... | BURNS M MICHELE | Director | Option Exercise | A | 138.86 | 2,294 | 318,545 | 2,294 | |
May 13 2016 | ALXN | ALEXION PHARMACEUT ... | BURNS M MICHELE | Director | Grant | A | 0.00 | 835 | 0 | 2,323 | 1.5 K to 2.3 K (+56.12 %) |
May 13 2016 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 138.65 | 53 | 7,348 | 32,337 | 32.4 K to 32.3 K (-0.16 %) |
May 13 2016 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Option Exercise | A | 138.86 | 2,294 | 318,545 | 2,294 | |
May 13 2016 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Grant | A | 0.00 | 835 | 0 | 7,073 | 6.2 K to 7.1 K (+13.39 %) |
May 13 2016 | ALXN | ALEXION PHARMACEUT ... | BAKER FELIX | Director | Option Exercise | A | 138.86 | 2,294 | 318,545 | 2,294 | |
May 13 2016 | ALXN | ALEXION PHARMACEUT ... | BAKER FELIX | Director | Grant | A | 0.00 | 835 | 0 | 6,104,562 | 6.1 M to 6.1 M (+0.01 %) |
May 13 2016 | ALXN | ALEXION PHARMACEUT ... | BAKER FELIX | Director | Grant | A | 0.00 | 835 | 0 | 507,696 | 506.9 K to 507.7 K (+0.16 %) |
Apr 05 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Sell | S | 136.21 | 34 | 4,631 | 189,598 | 189.6 K to 189.6 K (-0.02 %) |
Apr 05 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Sell | S | 135.87 | 1,380 | 187,501 | 189,632 | 191 K to 189.6 K (-0.72 %) |
Mar 04 2016 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 149.55 | 651 | 97,357 | 36,034 | 36.7 K to 36 K (-1.77 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Option Exercise | A | 140.16 | 21,000 | 2,943,360 | 21,000 | |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 138.91 | 547 | 75,984 | 32,390 | 32.9 K to 32.4 K (-1.66 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Grant | A | 0.00 | 3,000 | 0 | 32,937 | 29.9 K to 32.9 K (+10.02 %) |
Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Option Exercise | A | 140.16 | 31,000 | 4,344,960 | 31,000 |